Cargando…

Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2

Novel coronavirus disease 2019 (COVID-19) causes pulmonary and cardiovascular disorders and has become a worldwide emergency. Myocardial injury can be caused by direct or indirect damage, particularly mediated by a cytokine storm, a disordered immune response that can cause myocarditis, abnormal coa...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Anjos, Fernanda, Simões, Júlia Leão Batista, Assmann, Charles Elias, Carvalho, Fabiano Barbosa, Bagatini, Margarete Dulce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709498/
https://www.ncbi.nlm.nih.gov/pubmed/33299899
http://dx.doi.org/10.1155/2020/8632048
_version_ 1783617762524921856
author dos Anjos, Fernanda
Simões, Júlia Leão Batista
Assmann, Charles Elias
Carvalho, Fabiano Barbosa
Bagatini, Margarete Dulce
author_facet dos Anjos, Fernanda
Simões, Júlia Leão Batista
Assmann, Charles Elias
Carvalho, Fabiano Barbosa
Bagatini, Margarete Dulce
author_sort dos Anjos, Fernanda
collection PubMed
description Novel coronavirus disease 2019 (COVID-19) causes pulmonary and cardiovascular disorders and has become a worldwide emergency. Myocardial injury can be caused by direct or indirect damage, particularly mediated by a cytokine storm, a disordered immune response that can cause myocarditis, abnormal coagulation, arrhythmia, acute coronary syndrome, and myocardial infarction. The present review focuses on the mechanisms of this viral infection, cardiac biomarkers, consequences, and the possible therapeutic role of purinergic and adenosinergic signalling systems. In particular, we focus on the interaction of the extracellular nucleotide adenosine triphosphate (ATP) with its receptors P2X1, P2X4, P2X7, P2Y1, and P2Y2 and of adenosine (Ado) with A2A and A3 receptors, as well as their roles in host immune responses. We suggest that receptors of purinergic signalling could be ideal candidates for pharmacological targeting to protect against myocardial injury caused by a cytokine storm in COVID-19, in order to reduce systemic inflammatory damage to cells and tissues, preventing the progression of the disease by modulating the immune response and improving patient quality of life.
format Online
Article
Text
id pubmed-7709498
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-77094982020-12-08 Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2 dos Anjos, Fernanda Simões, Júlia Leão Batista Assmann, Charles Elias Carvalho, Fabiano Barbosa Bagatini, Margarete Dulce J Immunol Res Review Article Novel coronavirus disease 2019 (COVID-19) causes pulmonary and cardiovascular disorders and has become a worldwide emergency. Myocardial injury can be caused by direct or indirect damage, particularly mediated by a cytokine storm, a disordered immune response that can cause myocarditis, abnormal coagulation, arrhythmia, acute coronary syndrome, and myocardial infarction. The present review focuses on the mechanisms of this viral infection, cardiac biomarkers, consequences, and the possible therapeutic role of purinergic and adenosinergic signalling systems. In particular, we focus on the interaction of the extracellular nucleotide adenosine triphosphate (ATP) with its receptors P2X1, P2X4, P2X7, P2Y1, and P2Y2 and of adenosine (Ado) with A2A and A3 receptors, as well as their roles in host immune responses. We suggest that receptors of purinergic signalling could be ideal candidates for pharmacological targeting to protect against myocardial injury caused by a cytokine storm in COVID-19, in order to reduce systemic inflammatory damage to cells and tissues, preventing the progression of the disease by modulating the immune response and improving patient quality of life. Hindawi 2020-12-01 /pmc/articles/PMC7709498/ /pubmed/33299899 http://dx.doi.org/10.1155/2020/8632048 Text en Copyright © 2020 Fernanda dos Anjos et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
dos Anjos, Fernanda
Simões, Júlia Leão Batista
Assmann, Charles Elias
Carvalho, Fabiano Barbosa
Bagatini, Margarete Dulce
Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2
title Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2
title_full Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2
title_fullStr Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2
title_full_unstemmed Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2
title_short Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2
title_sort potential therapeutic role of purinergic receptors in cardiovascular disease mediated by sars-cov-2
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709498/
https://www.ncbi.nlm.nih.gov/pubmed/33299899
http://dx.doi.org/10.1155/2020/8632048
work_keys_str_mv AT dosanjosfernanda potentialtherapeuticroleofpurinergicreceptorsincardiovasculardiseasemediatedbysarscov2
AT simoesjulialeaobatista potentialtherapeuticroleofpurinergicreceptorsincardiovasculardiseasemediatedbysarscov2
AT assmanncharleselias potentialtherapeuticroleofpurinergicreceptorsincardiovasculardiseasemediatedbysarscov2
AT carvalhofabianobarbosa potentialtherapeuticroleofpurinergicreceptorsincardiovasculardiseasemediatedbysarscov2
AT bagatinimargaretedulce potentialtherapeuticroleofpurinergicreceptorsincardiovasculardiseasemediatedbysarscov2